A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

105 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-13

Study Completion Date

2028-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of APG-5918 in Healthy Subjects or Anemic Patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia

NCT05660785

Non Severe Aplastic Anemia Untreated

COMPLETED PHASE2

Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

NCT04815603

Anemia

WITHDRAWN PHASE2

A Bioequivalence Study of Hetrombopag in Healthy Subjects

NCT05088655

Sever Aplastic Anaemia

COMPLETED PHASE1

A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia

NCT02964936

Chronic Kidney Disease

COMPLETED PHASE3

A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

NCT03559699

Pyruvate Kinase Deficiency Anemia, Hemolytic

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial has two parts. Part A is a randomized, double-blind, placebo- controlled, single-dose escalation study in up to 7 cohorts to evaluate the safety, tolerability, and PK characteristics of APG-5918 in healthy subjects and to explore whether MTDS will be achieved within the range of projected therapeutic doses for anemia.

Part B is an opened-label,, multi-dose escalation trial in up to 6 cohorts to evaluate the safety, tolerability, PK and preliminary efficacy of APG-5918 in anemic subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)

Subjects will be randomized to receive a single dose of APG-5918 or placebo.

Group Type EXPERIMENTAL

APG-5918

Intervention Type DRUG

oral tablets 10mg, 50mg, 200mg.

Placebo

Intervention Type DRUG

Matching placebo

Multiple Ascending Dose (MAD) cohorts in Anemic Patients (Part B)

Subjects will receive once daily APG-5918 for 84 days or till EOT.

Group Type EXPERIMENTAL

APG-5918

Intervention Type DRUG

oral tablets 10mg, 50mg, 200mg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APG-5918

oral tablets 10mg, 50mg, 200mg.

Intervention Type DRUG

Placebo

Matching placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

1. Age ≥ 18 years and ≤ 55 years.
2. Body mass index (BMI) 18\~28kg/m² (inclusive).
3. Hb: 120 g/L\~160 g/L (inclusive).
4. Normal iron stores (normal serum iron and serum ferritin).

1. Age ≥ 18 years.
2. Chronic patients with anemia, including but not limited to β-thalassemia, with Hb ≤ 100 g/L at screening.
3. BMI: 16\~32 kg/m2 (inclusive).
4. Serum folate and vitamin B12 levels above lower limit of normal (LLN).
5. Ferritin ≥ 40 ng/mL.
6. ALT, AST ≤ 2 × ULN, or Direct (Unbound) total bilirubin (DBIL) ≤ 2.0× ULN.
7. No active or chronic bleeding.
8. ECOG performance status score of 0 to 1.

3\. Female subjects of childbearing potential who have a negative serum or urine pregnancy test within 7 days prior to the first dose.

4\. Subjects and their partners volunteer to use protocol-specified effective contraception during treatment and for at least 3 months after the last dose of study drug (see Section 8.7 for details).

5\. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the subject prior to any study-specific procedures).

Exclusion Criteria

1. History of any disease or clinical condition that, in the opinion of the investigator, could confound the results of the study or pose an additional risk to the subject by administering study drug. Including but not limited to history or presence of cardiac, endocrine, hematologic, hepatic, gastrointestinal, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other diseases.
2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 × upper limit of normal (ULN), or total bilirubin (TBIL) \> 1.5 × ULN at screening.
3. Surgery (except minor cosmetic surgery or minor dental surgery) within 3 months prior to screening.
4. Blood donation or blood loss of more than 400 ml within 3 months before screening or plans to donate blood or blood components during the study.
5. Use of another investigational product within 30 days or 5 half-lives, whichever is longer, or currently participating in a prospective study of an investigational product or medical device.
6. History of addictive substance abuse.
7. Alcohol breath test fails.

1. Clinically significant or uncontrolled persistent autoimmune diseases (e.g., rheumatoid arthritis, Crohn's disease, celiac disease, etc.).
2. Uncontrolled hypertension (diastolic blood pressure \> 110 mmHg or systolic blood pressure \> 170 mmHg at screening) or diabetes as judged by the investigator.
3. New York Heart Association Class II to IV congestive heart failure, or recent myocardial infarction or acute coronary syndrome.
4. History of diagnosis of persistent hemolysis or hemolytic syndrome except for hypoferric anemia and beta-thalassemia.
5. History of thrombosis or new blood clots within 4 weeks prior to screening.
6. Any active infection requiring systemic antibiotics within 14 days prior to the first dose administration.
7. Intravenous iron within 28 days prior to screening.
8. Previous history of organ transplantation.
9. Patients who participated in other clinical studies within 4 weeks prior to the first dose administration and were still taking other study drugs or had not exceeded 5 half-lives.

3.Positive screening results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus antibody (HIV Ab), or treponema pallidum antibody at screening.

4.Standard 12-lead ECG QTcB \> 450 ms in men and \> 470 ms in women. 5. History of regular alcohol consumption within 6 months before screening, daily average intake of ethanol ≥ 30 grams (male) or ≥ 20 grams (female).

6\. Female subjects who are pregnant, planning to become pregnant, or breastfeeding, or male subjects whose partners intend to become pregnant.

7\. Any subject who is not suitable for participating in this study as judged by the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes